发布求助
文献互助 智能选刊 最新文献

Skin therapy letter最新文献

筛选
英文 中文
Deuruxolitinib for Alopecia Areata. deurxolitinib治疗斑秃。
Skin therapy letter Pub Date : 2026-01-01
Alexander Robbins, Mariana Phillips
{"title":"Deuruxolitinib for Alopecia Areata.","authors":"Alexander Robbins, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alopecia areata (AA), an autoimmune condition characterized by non-scarring hair loss, affects 2% of the United States population. AA is a CD8 T-cell driven autoimmune disease in which the cytokines interferon-gamma and interleukin-15 play a central role in disease progression. These pathways depend on Janus kinase (JAK) signaling, making JAK inhibitors an ideal therapeutic option in treating AA. Deuruxolitinib, an oral JAK inhibitor, was approved by the US Food and Drug Administration in July 2024, for the treatment of severe AA in adults. Deuruxolitinib is the third oral JAK inhibitor approved for the treatment of severe AA, the others being baricitinib and ritlecitinib. Deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in the treatment of AA are reviewed.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"31 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data. OX40配体抑制剂治疗中重度特应性皮炎：II期临床试验数据综述
Skin therapy letter Pub Date : 2025-11-01
Siddhartha Sood, Alim R Devani, Tiago Torres, Jensen Yeung, Vimal H Prajapati
{"title":"OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data.","authors":"Siddhartha Sood, Alim R Devani, Tiago Torres, Jensen Yeung, Vimal H Prajapati","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common, chronic immune-mediated inflammatory skin disease. The OX40-OX40 ligand (OX40L) pathway has emerged as a novel therapeutic target. On this basis, three phase II clinical trials have been conducted to evaluate the efficacy and safety of three different OX40-OX40L inhibitors (amlitelimab, rocatinlimab, and telazorlimab) in moderate-to-severe AD. Herein, we review the published data from these studies.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 6","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145725944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma. 新辅助免疫治疗在皮肤鳞状细胞癌治疗中的应用。
Skin therapy letter Pub Date : 2025-11-01
Christopher Guirguis, Lauren Ching, Mariana Phillips
{"title":"Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma.","authors":"Christopher Guirguis, Lauren Ching, Mariana Phillips","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Immunotherapy has shown promise in treating locally advanced, recurrent, and metastatic cutaneous squamous cell carcinoma. More recently, studies have shown the role of immunotherapy as neoadjuvant treatment in advanced disease for which surgery may not be curative or would be expected to result in functional or cosmetic morbidity. This paper reviews data showing the safety and efficacy of cemiplimab as neoadjuvant treatment in cutaneous squamous cell carcinoma. Early findings suggest that neoadjuvant immunotherapy may help improve surgical outcomes by reducing tumor burden before resection.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 6","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145725988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib. 1型神经纤维瘤病的治疗进展：以塞鲁美替尼为重点。
Skin therapy letter Pub Date : 2025-09-01
Faith Cormier, Irene Lara-Corrales, Maxwell Sauder, Rebecca Levy
{"title":"Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.","authors":"Faith Cormier, Irene Lara-Corrales, Maxwell Sauder, Rebecca Levy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neurofibromatosis type 1 (NF1) is a genetic condition inherited in an autosomal dominant pattern, but with 50% of cases caused by de novo mutations. Neurofibromin, the gene product in NF1, regulates the RAS/MAPK pathway, and mutation can lead to cell proliferation and the development of tumours. NF1 often presents in childhood with cafe-au-lait macules, skinfold freckling, nervous system tumours, and phenotypically variable findings. Plexiform neurofibromas (PN), a type of peripheral nerve sheath tumour seen in NF1, are typically histologically benign. However, PN can cause significant physical disfigurement, pain, and decreased quality of life, and have historically been difficult to treat. Selumetinib, a MEK inhibitor inhibiting the RAS/MAPK pathway, was Health Canada approved in 2022 for the treatment of symptomatic, inoperable PN in individuals with NF1 aged 2 years and older. Phase 1 and 2 trials have demonstrated reduced tumour size, decreased disfigurement and pain, and increased quality of life.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 5","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis. Upadacitinib治疗特应性皮炎的长期安全性和有效性综述。
Skin therapy letter Pub Date : 2025-09-01
Mohamad R Taha, Stephen K Tyring
{"title":"A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Upadacitinib, a JAK inhibitor, has been approved for the treatment of moderate-to-severe AD. This review evaluates the long-term safety and efficacy of upadacitinib in AD, incorporating findings from the Measure Up 1 and Measure Up 2 phase 3 studies.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 5","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis Lebrikizumab用于中重度特应性皮炎。
Skin therapy letter Pub Date : 2025-07-01
Leah Johnston, Susan Poelman, Andrei Metelitsa
{"title":"Lebrikizumab for Moderate-to-Severe Atopic Dermatitis","authors":"Leah Johnston, Susan Poelman, Andrei Metelitsa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13. In June 2024, lebrikizumab was approved by Health Canada for the treatment of moderate-to-severe AD in adults and adolescents who are 12 years of age and older, followed by US Food and Drug Administration approval in September 2024. This review provides an overview of data from clinical trials on the efficacy and safety of lebrikizumab in adult patients.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 4","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanodermatology Nanodermatology。
Skin therapy letter Pub Date : 2025-07-01
Claire Fason, Stephen K Tyring
{"title":"Nanodermatology","authors":"Claire Fason, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nanodermatology has been an emerging area of research and drug development in the last two decades. Nanodermatology lies at the intersection of nanotechnology, chemical engineering, biophysics, and pharmacology. Increasing research has yielded potential benefits of nanotechnology in the treatment of various skin conditions via enhanced transdermal drug delivery. Nanoparticles, defined as particles ranging from 1 to 1000 nanometers, have been more frequently explored for their potential role in targeted drug delivery systems. Nanocarriers, which include liposomes, ethosomes, and vesicle carriers, have been increasingly investigated to improve efficacy of various drugs via enhanced delivery to the target site. Many dermatologic conditions are preferentially treated with topical formulations to locally target the affected area and reduce systemic absorption, but these formulations are limited in their penetration. The ability of topical formulations to effectively deliver active ingredients to the target site is uncertain, therefore nanoparticles have been increasingly investigated as an approach to boost drug delivery to the deeper layers of the skin, improve absorption, and decrease adverse effects. Enhanced drug delivery utilizing nanoparticles has been successfully trialed for treatment of psoriasis, vitiligo, acne vulgaris, and atopic dermatitis in many research studies, however more investigation is needed prior to utilization in humans.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 4","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis 奈莫单抗用于治疗结节性痒疹和特应性皮炎。
Skin therapy letter Pub Date : 2025-05-01
Mohamad R Taha, Stephen K Tyring
{"title":"Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 3","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne. 一种治疗中重度痤疮的新型固定剂量三联疗法（IDP-126）。
Skin therapy letter Pub Date : 2025-05-01
Karen Michael, Jaefer Mohamad, Nuha Nasir, Jerry Tan
{"title":"A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne.","authors":"Karen Michael, Jaefer Mohamad, Nuha Nasir, Jerry Tan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126) is a novel fixed-dose triad gel combination approved by the US FDA October 2023 and by Health Canada August 2024 for the treatment of acne vulgaris in patients aged 12 years and older. IDP-126 was efficacious in moderate to severe acne compared to vehicle and component topical dyads in phase 2 and to vehicle in phase 3 randomized controlled studies. Efficacy outcomes were inflammatory and noninflammatory lesion counts and Evaluator's Global Severity Score. IDP-126 also had a favorable tolerability and safety profile.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 3","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roflumilast for the Treatment of Seborrheic Dermatitis: A Review. 罗氟司特治疗脂溢性皮炎的研究进展。
Skin therapy letter Pub Date : 2025-03-01
Austinn C Miller, Abigail E Watson, Marc J Inglese
{"title":"Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.","authors":"Austinn C Miller, Abigail E Watson, Marc J Inglese","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.</p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 2","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书